NeuroOne Medical Technologies Corp

NeuroOne Medical’s insider buying shows executives bet on its quantum‑computing pivot—4% of shares now held, 95% YTD gain, but investors should weigh risk factors and liquidity concerns.

Insider sales at NeuroOne don’t signal distress—OneRF’s strong safety profile, 510(k) clearance, and promising clinical data keep the company poised for upside.